The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness

Foramen Ovale, Patent Clinical Trial

Official title:

Feasibility Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00196040
• Other study ID #: 2005-002
• Status: Completed
• Phase: N/A
• First received: September 12, 2005
• Last updated: December 18, 2007
• Start date: October 2005
• Est. completion date: November 2007

Study information

• Verified date: December 2007
• Source: Cierra
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to demonstrate the safety and efficacy of the PFX Closure System when utilized for patent foramen ovale (PFO) in patients suffering from cryptogenic stroke (undetermined cause of stroke), transient ischemic attack (brief neurological dysfunction), migraine or decompression illness.

Description:

Patent Foramen Ovale has been implicated in the etiology of paradoxical embolism, cryptogenic stroke, transient ischemic attack, and right to left gas embolism in severe decompression illness. An association between patent foramen ovale and severe migraine headaches has also been reported. Several implantable devices are being used for percutaneous closure of patent foramen ovale; we propose to use a non-implantable system to safely effect closure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: November 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subject is between 18 and 65 years old

• Documented patent foramen ovale as determined by positive micro bubble study demonstrating right to left shunt and/or anatomic detection and functional assessment by pre-operative transcranial Doppler (TCD) and peri-operative echocardiography or ultrasound.

• Subjects with one or more of the following:

• history of cryptogenic stroke, transient ischemic attack (TIA) or embolism due to presumed paradoxical embolism through a PFO; or

• history of severe migraine headaches, despite attempted treatment with available migraine medications, for whom other specific causes of migraine headache, such as underlying disease or medications, have been ruled out; or

• history of severe decompression illness.

• Negative pregnancy test in women who are of child-bearing potential

• Signed Informed Consent form

Additional Inclusion Criteria for Migraine Subjects:

• Onset of migraine before age of 50 years

• History of migraine > 1 year

• Migraine frequency greater than 1 migraine per month

Exclusion Criteria:

• Presence of thrombus at the intended site of closure, in left atrial appendage, or documented evidence of venous thrombus in the vessels through which access to the PFO is gained.

• Active endocarditis, or other infections producing a bacteremia

• Presence of atrial septal defect(s) or fenestrations which allow shunting

• Presence of implanted cardiac valves, pacemakers, cardioverters/defibrillators (ICDs) or vena cava filters.

• Subjects with coagulation disorders or bleeding disorders including gastric ulcers, who are unable to take antiplatelet or anticoagulant therapy

• Subjects with an intra-cardiac mass, tumor, clots or vegetation

• Large, redundant atrial septal aneurysm that would prohibit adequate device access to the PFO or closure of the PFO, in the judgment of the investigator. A coexisting redundant atrial septal aneurysm is considered large if it prohibits the ability of the operator to adequately achieve vacuum suction necessary to achieve PFO closure.

• Presence of conduction abnormality requiring pharmacologic or electrical therapy intervention or 1st degree block

• Current enrollment in any investigational trial(s) using devices implanted in the vascular system or enrolled in any experimental drug study(ies) within three months of study entry

• Religious or other beliefs which would prevent subjects from following all physician directed instructions or prevent compliance with protocol required medications and follow-ups.

• Hemodynamic instability or shock

• History of diabetes requiring treatment with insulin

Additional Exclusion Criteria for Cryptogenic Stroke Subjects:

• History of stroke or TIA within the past 14 days

• Source of stroke other than paradoxical embolization

Additional Exclusion Criteria for Migraine Subjects:

• Seizure disorder

• Other organic central nervous system disease

• Headache as a result of traumatic head or neck injury

• Evidence of alcohol, drug or substance abuse within the previous year

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Foramen Ovale, Patent
• Ischemic Attack, Transient

Intervention

Device:
• PFX Closure System

Locations

Country	Name	City	State
Germany	Cardiovascular Center Frankfurt Sankt katharinen	Frankfurt

Sponsors (1)

Lead Sponsor	Collaborator
Cierra

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFO closure as measured by transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE) acutely post procedure
Secondary	PFO closure as measured by TEE or transthoracic echocardiography (TTE) at 30 days, 3 or 6 months and 12 months post procedure
Secondary	Adverse event (AE) rates for all subjects
Secondary	New conduction abnormality rate through final follow-up
Secondary	Measurement of migraine severity or frequency at 6 and 12 months post procedure for subjects enrolled due to diagnosis of migraine